Prostate Cancer Clinical Trials in Colorado

Showing 21-40 of 270 trials

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

NCT07332000

Phase 2a, open-label, multi-center study evaluating biomarkers and biodistribution of aglatimagene besadenovec plus valacyclovir in men with localized, intermediate-risk prostate cancer who are planning to receive external beam radiation therapy (EBRT).

Prostate Cancer Patients Treated by RadiotherapyProstate Cancer (Adenocarcinoma)

Candel Therapeutics, Inc.45 participantsStarted Oct 2025

Peoria, Arizona, United States • Lakewood, Colorado, United States • Littleton, Colorado, United States +4 more locations

RECRUITINGPhase 141 miles

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

NCT05176483

This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alone, and in combination with nivolumab (doublet), nivolumab + ipilimumab (triplet) and nivolumab + relatlimab (triplet) in participants with advanced solid tumors. In the Expansion Stage, the safety and efficacy of zanzalintinib as monotherapy and in combination therapy will be further evaluated in tumor-specific Expansion Cohorts.

Renal Cell Carcinoma (RCC)Metastatic Castration-Resistant Prostate Cancer (mCRPC)Urothelial Carcinoma (UC)+7 more

Exelixis1,314 participantsStarted Dec 2021

Phoenix, Arizona, United States • Tucson, Arizona, United States • Palo Alto, California, United States +119 more locations

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

Prostate Cancer Trials in Other Cities

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

A Multi-modal, Physician-centered Intervention to Improve Guideline-concordant Prostate Cancer Imaging

Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.

Predictors of Mental Health in Men With Prostate Cancer Undergoing a Patient Empowerment Program

Other Conditions in Colorado